New drug avapritinib under Real-World watch for mastocytosis relief
NCT ID NCT07255638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 80 people in Germany with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. Researchers will track how avapritinib affects quality of life and symptom control over up to 24 months in everyday medical practice. The goal is to see how well the drug works outside of a controlled trial setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT SYSTEMIC MASTOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie
RECRUITINGBerlin, 10117, Germany
-
HNO-Gemeinschaftspraxis Wiesbaden, GEKA Gesellschaft für Experimentelle und Klinische Atemwegsforschung mbH, Zentrum für Rhinologie und Allergologie
RECRUITINGWiesbaden, 65205, Germany
-
Helios Universitätsklinikum Wuppertal
RECRUITINGWuppertal, 42283, Germany
-
Katholisches Klinikum Bochum
RECRUITINGBochum, 44791, Germany
-
MVZ Klinikum Deggendorf
RECRUITINGDeggendorf, 94469, Germany
-
Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie
RECRUITINGTübingen, 72076, Germany
-
University Medical Center Goettingen - Georg August University of Goettingen
RECRUITINGGöttingen, 37075, Germany
-
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie
RECRUITINGDresden, 01307, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.